Tech Company Financing Transactions
AlgoTx Funding Round
AlgoTx closed a $21.2 million Series B funding round on 3/15/2023. Investors included Bpifrance, InnoBio Fund and OMNES Capital.
Transaction Overview
Company Name
Announced On
3/15/2023
Transaction Type
Venture Equity
Amount
$21,227,000
Round
Series B
Proceeds Purpose
The company intends to use the funds to accelerate its development efforts to demonstrate the clinical efficacy of ATX01 in neuropathic pain.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
49 rue des Nouvelles
Suresnes, 92150
FR
Suresnes, 92150
FR
Phone
Undisclosed
Website
Email Address
Overview
At AlgoTx we develop novel solutions to relieve patients with difficult-to-treat « Complex Pain. We do so by prioritizing indications that have no proven and approved therapy, and tailoring treatment to the very specific needs of the affected patients. FDA aprouved ATX01's entry into Phase 2 in Chemotherapy-Induced Peripheral Neuropathy. In parallel, we are exploring its potential in a rare and painful disease, erythromelalgia. ATX01's topical administration enables the direct blockade of pain messaging in the nerve fibers of the skin, and limits the systemic side-effects potential associated with oral or intravenous drugs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stéphane Thiroloix
Co-Founder
Olivier Bohuon
Browse more venture capital transactions:
Prev: 3/15/2023: Intelligent Fluids venture capital transaction
Next: 3/15/2023: Payabli venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs